Evidence map›Paper›PMID 41983618›Full record

Trial reportJournal of the American College of Cardiology2026

Risk-Guided Atrial Fibrillation Screening With Artificial Intelligence-Enabled Electrocardiogram Models: A VITAL-AF Trial Analysis.

Natasha A Vedage, Sam F Friedman, Yuchiao Chang, Leila H Borowsky, Sachin J Shah, David D McManus, Steven J Atlas, Daniel E Singer, Steven A Lubitz, Mahnaz Maddah and 2 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in Journal of the American College of Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03515057 (Screening for Atrial Fibrillation in an Ambulatory Clinic Population), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03515057 naunknown statusnot on this map

Screening for Atrial Fibrillation in an Ambulatory Clinic Population: The VITAL-AF Study

TypeinterventionalSponsorMassachusetts General HospitalRan2018 to 2021Enrolled35,308ConditionsAtrial FibrillationArmsSingle lead handheld electrocardiogram
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. [Atrial fibrillation screening-reading the P-wave].Innere Medizin (Heidelberg, Germany) · 2026
    Review
  2. Article
  3. Procedural Management of Atrial Fibrillation in Older Patients.Reviews in cardiovascular medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Natasha A VedageCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiovascular Research Center, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA; Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA.
Sam F FriedmanData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Yuchiao ChangDivision of General Internal Medicine, Mass General Brigham, and Harvard Medical School, Boston, Massachusetts, USA.
Leila H BorowskyDivision of General Internal Medicine, Mass General Brigham, and Harvard Medical School, Boston, Massachusetts, USA.
Sachin J ShahDivision of General Internal Medicine, Mass General Brigham, and Harvard Medical School, Boston, Massachusetts, USA.
David D McManusDepartment of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
Steven J AtlasDivision of General Internal Medicine, Mass General Brigham, and Harvard Medical School, Boston, Massachusetts, USA.
Daniel E SingerDivision of General Internal Medicine, Mass General Brigham, and Harvard Medical School, Boston, Massachusetts, USA.
Steven A LubitzTelemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA.
Mahnaz MaddahData Sciences Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Patrick T EllinorCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiovascular Research Center, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA; Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA.
Shaan KhurshidCardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Cardiovascular Research Center, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA; Telemachus and Irene Demoulas Family Foundation Center for Cardiac Arrhythmias, Heart and Vascular Institute, Mass General Brigham, Boston, Massachusetts, USA. Electronic address: skhurshid@mgb.org.

Funding

The Center for Advancing Point of Care in Heart, Lung, Blood and Sleep DiseasesU54HL143541 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Nathaniel Scott Hafer · 2018 to 2026
$141.0M
IDENTIFICATION OF COMMON GENETIC VARIANTS FOR ATRIAL FIBRILLATION AND PR INTERVALR01HL092577 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI BENJAMIN, EMELIA J., ELLINOR, PATRICK THOMAS · 2009 to 2025
$20.6M
SUPPORT-AF IVR01HL155343 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KAPOOR, ALOK · 2021 to 2025
$3.4M
Genomics of Cardiac ArrhythmiasR01HL139731 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS · 2018 to 2022
$3.3M
Using Electrocardiogram Genetics to Inform Arrhythmia RiskR01HL157635 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ELLINOR, PATRICK THOMAS, MIRSHAHI, TOORAJ · 2022 to 2025
$2.9M
IMPACT: Integrative Mindfulness-Based Predictive Approach for Chronic low back pain TreatmentUG3NS135168 · NINDS · WORCESTER POLYTECHNIC INSTITUTE · PI AGU, EMMANUEL, KING, JEAN A · 2023 to 2023
$1.6M
Individualizing Anticoagulant use in Older Adults with Atrial FibrillationK76AG074919 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHAH, SACHIN J · 2021 to 2025
$1.2M
Electrocardiogram-based deep learning and decision analysis to improve atrial fibrillation risk estimationK23HL169839 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Shaan Khurshid · 2023 to 2026
$860k
American Heart Association-American Stroke Association 23CDA1050571NHLBI NIH HHS K23 HL169839NHLBI NIH HHS R01 HL092577NHLBI NIH HHS R01 HL139731NHLBI NIH HHS R01 HL155343NHLBI NIH HHS R01 HL157635NHLBI NIH HHS U54 HL143541NIA NIH HHS K76 AG074919NINDS NIH HHS UG3 NS135168
6 · The paper itself

Abstract

backgroundScreening for atrial fibrillation (AF) may lead to earlier detection and initiation of preventive measures. Current AF screening approaches using a guideline age-based threshold of ≥65 years have shown limited yield.

objectivesIn an AF screening trial, we assessed whether the screening effect was larger among individuals at elevated AF risk using validated clinical and electrocardiogram (ECG)-based artificial intelligence (AI) risk models.

methodsVITAL-AF was a cluster-randomized trial of patients aged ≥65 years treated at 1 of 16 primary care practices affiliated with Massachusetts General Hospital. Patients randomized to a screening practice were screened using a single-lead ECG. Among VITAL-AF participants without prevalent AF with at least one 12-lead ECG within 3 years before enrollment, we estimated AF risk using 3 validated models derived outside of VITAL-AF: the Cohorts of Heart and Aging Research in Genomic Epidemiology-AF (CHARGE-AF) clinical score, an AI-based model using a 12-lead ECG alone (ECG-AI), and a model combining ECG-AI and CHARGE-AF (CH-AI). Two-year incident AF discrimination was assessed by the time-dependent area under the receiver-operating characteristic curve (AUROC) and average precision. AF screening effect was defined as the difference in 2-year incident AF diagnosis rate (per 100 person-years) in screening vs control across AF risk deciles.

resultsOf 30,630 VITAL-AF participants without prevalent AF, 16,937 had pretrial ECG and clinical data. Each score discriminated 2-year AF risk according to AUROC (CHARGE-AF: 0.711 [95% CI: 0.671-0.749]; ECG-AI: 0.784 [95% CI: 0.743-0.819]; CH-AI: 0.788 [95% CI: 0.754-0.824]) and average precision (0.0952 [95% CI: 0.0836-0.112]; 0.132 [95% CI: 0.113-0.157]; 0.133 [95% CI: 0.117-0.159]). An AF screening effect was observed in the top decile of CH-AI (AF diagnosis rate in screening 10.07/100 person-years [95% 8.28-11.87] vs 7.76 [95% 6.30-9.21] in control, P < 0.05), corresponding to a difference in AF diagnosis rate of 2.32/100 person-years (95% CI: 0.01-4.63) and number-needed-to-screen of 43 per year.

conclusionsUse of ECG-based AI and clinical factors identified individuals at particularly high risk for AF who may benefit from screening. Findings suggest a trade-off between increasing AF screening efficiency and decreasing population coverage (ie, restriction of the screening pool). Future studies are needed to determine whether a risk-based approach is optimal or whether consideration of additional clinical- and systems-level factors (eg, access, health care system engagement) can further refine AF screening strategies. (Screening for Atrial Fibrillation Among Older Patients in Primary Care Clinics [VITAL-AF]; NCT03515057).

Indexed as

Artificial IntelligenceAtrial FibrillationElectrocardiographyMass ScreeningAgedFemaleHumansMaleRisk Assessmentartificial intelligenceatrial fibrillationelectrocardiogramrandomized trialrisk predictionscreening

Identifiers

PMID41983618
PMCPMC13675868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.